MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market
This announcement contains inside information GAITHERSBURG, MD, July 26, [...]
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
GAITHERSBURG, MD, July 12, 2021 — MaxCyte, Inc., (LSE: [...]
Financial Information in the Form S-1 Registration Statement & Change to Board of Directors
GAITHERSBURG, MD, 12 July 2021 — MaxCyte, Inc., (LSE: [...]
MaxCyte Adds Two New Non-Executive Directors to Its Board
Gaithersburg, Maryland – June 15, 2021: MaxCyte, a [...]
Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates
Celularity to utilize MaxCyte’s Flow Electroporation® technology and [...]
Proposed Dual-Listing on Nasdaq
This announcement contains inside information GAITHERSBURG, MD, [...]
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
GAITHERSBURG, MD, February 23, 2021 — MaxCyte, Inc., [...]
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs
Myeloid to utilize MaxCyte’s Flow Electroporation® technology and [...]
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
Gaithersburg, Maryland – November 9, 2020: MaxCyte, Inc., a global [...]
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences
GAITHERSBURG, MD, November 9, 2020 — MaxCyte, Inc., a [...]
